Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MaaT013 plus ipilimumab and nivolumab in melanoma
2020-002932-64Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of MaaT013 in melanoma (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Safety. Started Mar 2021; status: active.
02
Drugs
MaaT013
03
Conditions
melanoma
Beyond the preview
Go deeper on 2020-002932-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002932-64.